Sun Pharma, AstraZeneca in mktg deal
Home  »  Community News  »  Sun Pharma, AstraZen...
Jun
4
ragupathyrenganathan
Sun Pharma, AstraZeneca in mktg deal
Pharma News
0

New Delhi: Drug majors Sun Pharmaceutical and AstraZeneca Pharma India (AZPIL) on Tuesday said they have entered into a distribution services agreement to distribute AstraZeneca’s heart disease treatment drug ‘Axcer’ in India.

“AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor,” Sun Pharma said. The company added that AZPIL already has a brand ‘Brilinta’ for ticagrelor molecule in India since 2012. Axcer is a drug used for the treatment of acute coronary syndrome (ACS).

Sanjay Murdeshwar, MD, AstraZeneca Pharma India, said: “Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient’s risk of another heart attack or cardiovascular-related death.”

The company further said: “This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby, benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy.”



Leave a reply

You must be logged in to post a comment.